Public reimbursement for biosimilar BYOOVIZ™ to treat serious retinal disorders now secured in four provinces and two national benefits programs
Yahoo! Finance USA,
Ontario and New Brunswick among latest jurisdictions to reimburse biosimilar of anti-VEGF ranibizumab, improving patient access…